
Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
KOD | US
-0.17
-6.39%
Healthcare
Biotechnology
30/09/2023
29/11/2023
2.49
2.65
2.75
2.46
Kodiak Sciences Inc. a clinical stage biopharmaceutical company researches develops and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301) an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD) as well as Phase III clinical study for the treatment of diabetic macular edema naïve macular edema due to retinal vein occlusion and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501 a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601 a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto California.
View LessLow Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
No Dividends (Dividend Yield = 0%)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
179.6%1 month
187.6%3 months
125.1%6 months
128.8%0
0
0.80
0.28
0.15
0.20
0
0
-272.88M
130.66M
130.66M
0
0
0
0
-69.42
7.62
9.74
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.90
Range1M
1.38
Range3M
1.39
Rel. volume
0.44
Price X volume
1.86M